To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

• Status: Completed
• Trial end date: 2020-11-10
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight® (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

• Informed consent obtained before any study-related activities. Study-related activities are any procedure related to recording of data according to the protocol

• Male and female patients with the diagnosis of haemophilia A

• Age range is 0 year and above

• A decision to initiate treatment with commercially available NovoEight® has been made by the patient/parent and the physician

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products

• Previous participation in this study. Participation is defined as informed consent obtained

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation